TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Positive Action for Social and Character Development
Brief Summary: This project focuses on social and character development of elementary and middle school-aged children and responds to an urgent national need that schools improve their capacity to address a range of student outcomes, including social skills, character, behavior, academic achievement and health outcomes. This study is a school-based randomized trial to evaluate the Positive Action program. The Positive Action program was designed to promote social and character development and improve behavior and school performance.


Options:
A: Arm Label: 7 Treatment Schools; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Action program | Arm Label: 7 Control Schools; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Positive Action program; Assigned to Arm(s): 7 Treatment Schools
B: Arm Label: School-based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Trial of Activity for Adolescent Girls (TAAG) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trial of Activity for Adolescent Girls (TAAG); Assigned to Arm(s): School-based intervention
C: Intervention Type: BEHAVIORAL; Name: In-school Sexual Health Education; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth-friendly health services; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth condom promotion & distribution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Community activities related to adolescent sexual health; Assigned to Arm(s): N/A
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: School children and adolescents as health experts | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: School children and adolescents as health experts; Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Positive Action for Social and Character Development
Brief Summary: This project focuses on social and character development of elementary and middle school-aged children and responds to an urgent national need that schools improve their capacity to address a range of student outcomes, including social skills, character, behavior, academic achievement and health outcomes. This study is a school-based randomized trial to evaluate the Positive Action program. The Positive Action program was designed to promote social and character development and improve behavior and school performance.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Risk Reduction through Family Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Risk Reduction through Family Therapy | Intervention Type: BEHAVIORAL; Name: Risk Reduction through Family Therapy; Assigned to Arm(s): 1, 2
B: Intervention Type: BEHAVIORAL; Name: Collaborative Behavioral Management; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Integrated parole and outpatient addiction treatment; Assigned to Arm(s): N/A
C: Arm Label: 7 Treatment Schools; Type: EXPERIMENTAL; Interventions: Behavioral: Positive Action program | Arm Label: 7 Control Schools; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Positive Action program; Assigned to Arm(s): 7 Treatment Schools
D: Arm Label: Miami Juvenile Drug Court-MDFT; Type: EXPERIMENTAL; Interventions: Behavioral: Miami Juvenile Drug Court-MDFT | Arm Label: Miami Juvenile Drug Court -TAU; Type: OTHER; Interventions: Behavioral: Miami Juvenile Drug Court -TAU | Intervention Type: BEHAVIORAL; Name: Miami Juvenile Drug Court-MDFT; Assigned to Arm(s): Miami Juvenile Drug Court-MDFT | Intervention Type: BEHAVIORAL; Name: Miami Juvenile Drug Court -TAU; Assigned to Arm(s): Miami Juvenile Drug Court -TAU

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: IVR-based Cognitive Behavior Therapy for Chronic Low Back
Brief Summary: The proposed study will test how well an innovative method, interactive voice response (IVR), can be used for delivering an treatment for chronic low back pain. The use of IVR will improve the accessibility of treatment to Veterans. IVR is a computerized interface that allows patients to use their telephone to: 1) obtain pre-recorded didactic information, 2) report data regarding pain-related symptoms and adherence to pain coping skill practice, and 3) receive personalized therapist feedback. Although CBT has been shown to be effective in reducing pain intensity, traditional CBT requires patients to make frequent office visits. The use of IVR will allow Veterans to access CBT from their home via a touch-tone telephone, thereby allowing them to access treatment at their convenience without travel to the VA for an outpatient appointment. Veterans with chronic low back pain will be randomized in equal numbers to receive either standard CBT or IVR-based CBT. Veterans in both conditions will receive 10 session of treatment designed to help them manage their chronic pain using pain coping skills. The primary outcome measure will be pain intensity.


Options:
A: Intervention Type: BEHAVIORAL; Name: Targeted parental instruction for positive lifestyle change with follow-up calls.; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: IVR based cognitive behavioral therapy | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Face to face cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: Face to face cognitive behavior therapy; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: IVR based cognitive behavioral therapy; Assigned to Arm(s): Arm 1
C: Arm Label: 1 - enhanced MI; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Motivational Interview | Arm Label: 2- standard MI; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Motivational Interview or viewing DVD | Intervention Type: BEHAVIORAL; Name: Enhanced Motivational Interview; Assigned to Arm(s): 1 - enhanced MI | Intervention Type: BEHAVIORAL; Name: Standard Motivational Interview or viewing DVD; Assigned to Arm(s): 2- standard MI
D: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Telephone behavioral education, Behavioral: Computer behavioral education | Intervention Type: BEHAVIORAL; Name: Telephone behavioral education; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Computer behavioral education; Assigned to Arm(s): Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12 Month, Multi-center, Randomized, Open-label Non-inferiority Study Comparing Safety and Efficacy of Concentration-controlled Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in de Novo Renal Transplant Recipients
Brief Summary: The purpose of this phase 3b study is to compare the safety and efficacy of everolimus with low dose tacrolimus to mycophenolate mofetil with standard dose tacrolimus in kidney transplant recipients.


Options:
A: Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus
B: Arm Label: EVR+rCNI; Type: EXPERIMENTAL; Interventions: Biological: Induction therapy, Drug: Corticosteroids, Drug: EVR+rCNI | Arm Label: MPA+sCNI; Type: ACTIVE_COMPARATOR; Interventions: Biological: Induction therapy, Drug: Corticosteroids, Drug: MPA+sCNI | Intervention Type: BIOLOGICAL; Name: Induction therapy; Assigned to Arm(s): EVR+rCNI, MPA+sCNI | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): EVR+rCNI, MPA+sCNI | Intervention Type: DRUG; Name: EVR+rCNI; Assigned to Arm(s): EVR+rCNI | Intervention Type: DRUG; Name: MPA+sCNI; Assigned to Arm(s): MPA+sCNI
C: Arm Label: TAC+MPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Enteric Coated Mycophenolate Sodium (EC-MPS), Drug: Mycophenolate mofetil (MMF), Drug: Corticosteroids, Drug: Simulect | Arm Label: TAC+Certican; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Tacrolimus, Drug: Corticosteroids, Drug: Simulect | Arm Label: CycA+Certican; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporin A, Drug: Corticosteroids, Drug: Simulect | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): CycA+Certican, TAC+Certican | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): TAC+Certican, TAC+MPA | Intervention Type: DRUG; Name: Cyclosporin A; Assigned to Arm(s): CycA+Certican | Intervention Type: DRUG; Name: Enteric Coated Mycophenolate Sodium (EC-MPS); Assigned to Arm(s): TAC+MPA | Intervention Type: DRUG; Name: Mycophenolate mofetil (MMF); Assigned to Arm(s): TAC+MPA | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): CycA+Certican, TAC+Certican, TAC+MPA | Intervention Type: DRUG; Name: Simulect; Assigned to Arm(s): CycA+Certican, TAC+Certican, TAC+MPA
D: Arm Label: Everolimus (EVR) & low dose of tacrolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus and tacrolimus | Arm Label: Mycophenolate mofetil & standard dose tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil and tacrolimus | Intervention Type: DRUG; Name: Everolimus and tacrolimus; Assigned to Arm(s): Everolimus (EVR) & low dose of tacrolimus | Intervention Type: DRUG; Name: mycophenolate mofetil and tacrolimus; Assigned to Arm(s): Mycophenolate mofetil & standard dose tacrolimus

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
Brief Summary: The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.


Options:
A: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection
B: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham
C: Arm Label: Intravitreous 2 mg aflibercept injections; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2-mg Intravitreous Aflibercept Injection | Arm Label: Prompt vitrectomy plus panretinal photocoagulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Prompt Vitrectomy Plus Panretinal Photocoagulation | Intervention Type: DRUG; Name: 2-mg Intravitreous Aflibercept Injection; Assigned to Arm(s): Intravitreous 2 mg aflibercept injections | Intervention Type: PROCEDURE; Name: Prompt Vitrectomy Plus Panretinal Photocoagulation; Assigned to Arm(s): Prompt vitrectomy plus panretinal photocoagulation
D: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
Brief Summary: The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.


Options:
A: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham
B: Arm Label: ETDRS-PRP group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: ETDRS-PRP group | Arm Label: ISQ-RP group; Type: EXPERIMENTAL; Interventions: Procedure: ISQ-RP | Intervention Type: PROCEDURE; Name: ISQ-RP; Assigned to Arm(s): ISQ-RP group | Intervention Type: PROCEDURE; Name: ETDRS-PRP group; Assigned to Arm(s): ETDRS-PRP group
C: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection
D: Arm Label: Panretinal Photocoagulation (PRP); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Panretinal Photocoagulation (PRP) | Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Intravitreous injection of ranibizumab | Arm Label: Ranibizumab + Panretinal Photocoagulation (PRP); Type: EXPERIMENTAL; Interventions: Procedure: Panretinal Photocoagulation (PRP), Drug: Intravitreous injection of ranibizumab | Intervention Type: PROCEDURE; Name: Panretinal Photocoagulation (PRP); Assigned to Arm(s): Panretinal Photocoagulation (PRP), Ranibizumab + Panretinal Photocoagulation (PRP) | Intervention Type: DRUG; Name: Intravitreous injection of ranibizumab; Assigned to Arm(s): Ranibizumab, Ranibizumab + Panretinal Photocoagulation (PRP)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
Brief Summary: The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.


Options:
A: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection
B: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham
C: Arm Label: Avastin Injection Group (AIG); Type: EXPERIMENTAL; Interventions: Drug: Avastin (bevacizumab) | Arm Label: Sham Injection Group (SIG); Type: SHAM_COMPARATOR; Interventions: Other: Sham injection | Intervention Type: DRUG; Name: Avastin (bevacizumab); Assigned to Arm(s): Avastin Injection Group (AIG) | Intervention Type: OTHER; Name: Sham injection; Assigned to Arm(s): Sham Injection Group (SIG)
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Procedure: pars plana vitrectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: pars plana vitrectomy | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: pars plana vitrectomy; Assigned to Arm(s): A, B

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravitreal Bevacizumab for Surgical Treatment of Severe Proliferative Diabetic Retinopathy
Brief Summary: The purpose of this study is to evaluate the role, the safety and the effectiveness of Intravitreal Bevacizumab injections as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy.


Options:
A: Arm Label: Ranibizumab 0.3 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Sham injection/ranibizumab 0.5 mg; Type: SHAM_COMPARATOR; Interventions: Drug: Sham injection | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab 0.3 mg, Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham injection; Assigned to Arm(s): Sham injection/ranibizumab 0.5 mg
B: Arm Label: 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: 20 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Other: sham | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 20 days, 7 days | Intervention Type: OTHER; Name: sham; Assigned to Arm(s): sham
C: Arm Label: Saline Injection; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Ranibizumab | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): Saline Injection
D: Arm Label: Placebo first (scheme 2); Type: OTHER; Interventions: Drug: potassium diclofenac | Arm Label: Diclofenac first (scheme 1); Type: OTHER; Interventions: Drug: potassium diclofenac | Intervention Type: DRUG; Name: potassium diclofenac; Assigned to Arm(s): Diclofenac first (scheme 1), Placebo first (scheme 2)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized,Double-Blind,Placebo-Controlled,Ascending,Single-Dose Study of the Safety,Tolerability and Bioeffect of Intravenously Administered REGN727 in Healthy Volunteers
Brief Summary: This study will test the safety and tolerability (how the body reacts to the drug) of REGN727 compared with placebo (an inactive substance that contains no medicine) in healthy subjects. The study drug and placebo will be administered by intravenous (I.V) infusion at one clinic visit. There will be 14 clinic visits, which will include 4 overnight stays. Subjects will be monitored by the study staff for side effects and the body's response to the study drug. Vital signs(blood pressure, temperature, breathing and heart rate) will be checked, and blood and urine samples will be collected at some or all visits.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 3; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 4; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Arm Label: cohort 5; Type: EXPERIMENTAL; Interventions: Drug: REGN727, Drug: Placebo | Intervention Type: DRUG; Name: REGN727; Assigned to Arm(s): Cohort 1, Cohort 2, cohort 3, cohort 4, cohort 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, cohort 3, cohort 4, cohort 5
B: Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for alirocumab); Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab, Placebo
D: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab 75 mg Q2W/Up to 150 mg Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for Alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W, Placebo Q2W

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of a Toolkit to Improve Cardiovascular Disease Screening and Treatment for People With Type 2 Diabetes
Brief Summary: Diabetes is a common and serious chronic disease. However, there is a large gap between the level of care that people should receive (based on research and guidelines) and the level of care they actually receive. With the release of their 2008 Clinical Practice Guidelines, the Canadian Diabetes Association has a strategy to improve heart disease screening and treatment for people with diabetes. This study will evaluate whether the strategy works. The focus of the strategy was to give all family physicians in Canada a Toolkit in June 2009 to help them delivery better care for their diabetic patients. In Ontario, only half of doctors received this Toolkit. We will compare the quality of care received by diabetic patients whose doctors received this Toolkit versus those who doctors did not.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Device: Accu-Chek Aviva Meter | Arm Label: B; Type: EXPERIMENTAL; Interventions: Device: Accu-Chek Aviva Meter | Intervention Type: DEVICE; Name: Accu-Chek Aviva Meter; Assigned to Arm(s): A | Intervention Type: DEVICE; Name: Accu-Chek Aviva Meter; Assigned to Arm(s): B
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telephone Counseling; Type: EXPERIMENTAL; Interventions: Other: Telephone counseling | Intervention Type: OTHER; Name: Telephone counseling; Assigned to Arm(s): Telephone Counseling
C: Arm Label: Medtable; Type: EXPERIMENTAL; Interventions: Behavioral: Medtable | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Medtable | Intervention Type: BEHAVIORAL; Name: Medtable; Assigned to Arm(s): Medtable, Usual care
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control

Answer: D